Member Info for dallo

Pawn
At the outrageous low SP buybacks are the perfect way to drive the SP higher given the relative illiquidity
in the share.
More returns to shareholders following Akili ( and Vedanta) listings and today is just the start in correcting the blatant SP undervaluation.

Nolupus
In fairness Franklin, Lisa ,the non executive Director plus other staff invested as well not to mention Alora ( Art Deas) chucking over £1.1m in the placing.
If IMMU can do a similar deal on the other peptide suite of drugs with a large Pharma as done with Alora
on Lupuzor then the cash needs of IMMU may not be significant.
All to play for here and the FDA decision on the Lupuzor Phase 3 trial could be transform the SP and allow an exit for some who don't wish to await the end results.
Still hold 2.5 m at average of 14p...stubborn is my middle name!

It looks like 5G offloaded a minimum of 1.2m shares over the past 5 months following its declaration of a holding of c6.5% in December.
Given the crash in tech stocks during this period and the illiquidity of ENET shares that has been enough to hammer the SP.
What is its motivation for doing such damage I wonder.
A supportive investor....I very much doubt it.
It is the responsibility of the company to maintain an orderly market in its shares and work in the interests of its shareholders.
It must now act accordingly imho.
Dyor

Skid
Fully agree .
SP collapse totally disproportionate to the number of shares sold....illiquidity can hammer a share on the downside as we are seeing today with no buyers at all.
A perfect hurricane for the poor ENET SP.
We will have to ride out the storm as selling now is madness imho.
ATB

I am still here suffering with the rest of you.
Bizarre crash in SP following an open and reasonably positive meeting in London.
Although I am not sure what way the attendees are feeling after the meeting facing a further 30% drop in our investment.
Our loyal funder 5G has no responsibility for ensuring an orderly market and appears to sell large blocks of shares no matter what the price or liquidity of the share.
I haven't sold any shares and hoping for good newsflow soon...now over 6 months since any positive RNS.
Dispiriting to say the least.
ATB

Puretech now looking at returning capital to shareholders via a number of avenues .
This is great news with Akili and Vedanta coming on the market soon when a % of Puretech stakes could liquidated and proceeds returned to Puretech shareholders in some form.
Management finally woken up to the valuation disconnect and is now going to act.
Should drive SP higher imho.

Skid
Fully understand...I was just looking for first names not surnames but I am sure we will have no problem identifying each other on Wednesday next
Cheers

As a matter of interest I would like to know who of the band of long term investors here are attending next week's investors meeting in London.
I will be there ..real name David Allen as a large investor with c 3.4% of the shares.
If anyone is attending let me know in advance so I will not be calling you by your pseudonym at the meeting.
I know Bid is Dan as he has been at the AGMS/ EGMS via video link during the pandemic so it would be nice to know attendees real names.
Just a thought
Looking forward to next week as surely ENET cannot be organising an investors forum without some positive output.
ATB

The share price is 7p and the market cap is £20m.
The almost certainty of the FDA approval of the Phase 3 Lupuzor trial will drive the SP much higher as the history of Phase 3 trials being successful after a PK study is 70% plus.
Royalties from the the US market with Avion will justify a market cap of $100m while rest of the world Royalties will add more significant value...US Lupus market expenditure is c60% of the rest of the world given the wealth of the US healthcare budgets.
Nobody should care about the 2 years of Lupuzor trials as Immupharma will be taken out quickly after the FDA decision imho maybe by Alora/Avion Pharma who are a $billion US private company and have a nice little stake already.
Imho
Dyor
Dyor

When I said that this board and others may have outlived their usefulness I am of course referring to this chat board and ADVFN.
But I am sure we will keep in touch nonetheless.
The investors meeting will be an ongoing thing I hope and will clarify/ nullify the speculation and arguments of many on the chat boards and making the chat boards then somewhat defunct.
ATB

I have 2.5m shares at 14p breakeven here.
What investors do not maybe understand that if the FDA approves the Phase 3 trial for Lupuzor and the Phase 1/2 trials for the other peptide therapies commence it doesn't matter a jot how long it takes to complete these trials the sheer value of success of these trials is so enormous that investors will take positions as the trials progress.
Maybe a major Pharma may move early to take a risk position given that is what they do with their own pipeline.
Phase 3 drug trials are the high % endgame for big Pharma so don't look at little Immupharma to bring the drugs to the market....it will be taken out well before that.
That is why it is a very good investment punt over the next few months....I see a 50p plus take out if the FDA approves the Lupuzor Phase 3 trial imho.
The PK successful trial makes the the FDA decision very likely imho.
DYOR

I shall be attending the investors forum with management after consisting advocating such a meeting for a long time.
I think this meeting is a sea change in investors relations by Ethernitys management.
The long termers here should welcome this and I feel
Management is now confident enough to have a face to face meeting with us and reflects growing confidence in the prospects for the company.
I feel this board and others may have outlived their usefulness and speculation and arguments will be superceded by real tangible performance by Ethernity.
At least I hope this will be the case.
Look forward to seeing some of the old band of brothers ( and sisters) at the investors meeting in London.
Cheers

Maybe we are all ( including myself) getting ahead of ourselves in extrapolating Taranas forecast growth with Ethernity's orders....paralysis through analysis comes to mind.
What has reassured me is that the relationship with Tarana which started with trials in 2017 is strengthening and will grow.....we just don't know at what pace yet.
The $3m order for 2023 is another positive although it should have maybe been RNSed.
I now await additional contract news which hopefully will add to the sticky customer and give the SP a lift.
Management is I feel fully aware that it cannot disappoint the market again this year and hence is rightly adopting a cautious approach imho.
Now off to Liverpool for the Benfica match with my son...come on the reds.
Dyor
Atb

Tarana achieved revenues of $10 million in the 4th quarter of 2021 with zero revenues in Q1 and revenues of c2/3 m total in Q2 and 3.
Total units sold in 2021 were 4,000 approx.
Tarana is forecasting 2022 revenues of $100m implying unit deliveries of c30,000 in 2022 with a doubling of units sold each year to 2026.
Tarana CEO Basil Alwan expects the company to list on Nasdaq in 2023 with a valuation anywhere north of $2/3 billion.
So on simple extrapolation of Taranas numbers and applying a sharp discount for risk factors, Ethernity sales to Tarana could be c$5m in 2022 and $15m in 2023 on a conservative assumption and potentially doubling each year thereafter PROVIDED Tarana meets its targets.
Ethernity can also presumably do business with other Wireless broadband operators worldwide.
I am confident that after the 2 Revenue "deferral" warnings last year the company's clear strategy this year is to under promise and over deliver on investor / market expectations .
I expect more positive newsflow during the coming months and I look forward to attending the AGM in May by which point I feel management and investors will hopefully be in a better frame of mind.
All my own meanderings....DYOR
ATB

01234
I have no doubt that Ethernity will produce significantly higher revenues than those in the outlook statements.
Management is now firmly committed imho to under
promise and over perform following the debacle of last year.
They know their reputations and cash is on the line this year.
Very confident again in the future of Ethernity.
DYOR

01234
I am more than confident that the 2022/23 outlook numbers are highly conservative as the Company will not make the embarrassing mistakes of 2 revenue deferral warnings ever again.
I also expect new contract announcements soon.
Just my thoughts.

Bod
Same here
MMs trying to open but no trading ...punters digesting results.
I expect a big bounce today but what do I know!

The reaffirmation of our relationship with Tarana and an uplift in the orders is massive and Tarana is set to grow over 10 fold in the next 2 years.
This is very important in my view as some people worried had our Tarana relationship waned.
Great news and only the beginning imho

Pre market bid/offer looks to show a 9%
drop in SP but this appears a knee jerk reaction by MMs to what are very reassuring figures and NED appointment.
I expect a bounce today although I have not delved deeply yet into the final accounts.

Bid
Results as expected but real reassurance in the cash figures plus hugely encouraging outlook for 2022/2023.
I am immensely relieved by the gross cash balance of c $7m as at 31st December 2021 which was added to by the recent $2m share subscription from 5G...now see clear path to profitability with sufficient cash resources.
Current SP was pricing the company as going broke and this has been shown to be nonsense now.
Also to add to the positive outlook...Ethernity has appointed a new NED who looks the part and would not have joined if he was not 100% confident in the company.
All in all my first read through is hugely positive and can see a rise in SP at open.
Dyor